Profile Name | KIT N822I |
Gene Variant Detail | |
Relevant Treatment Approaches | KIT Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KIT N822I | Advanced Solid Tumor | resistant | KIT Inhibitor | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT N822I demonstrated resistance to Gleevec (imatinib) in culture (PMID: 21689725). | 21689725 | KIT N822I | Advanced Solid Tumor | sensitive | KIT Inhibitor | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT N822I in culture (PMID: 21689725). | 21689725 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|